Merrimack Pharma-Ipsen''s Cancer Drug Fails In Overall Survival Measure
Merrimack Pharmaceuticals Inc''s (NASDAQ: MACK ) partner announced that Ipsen SA (OTC: IPSEY ) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study did not meet the primary endpoint of overall survival in patients treated with Onivyde … Full story available on Benzinga.com
Merrimack Pharma-Ipsen''s Cancer Drug Fails In Overall Survival Measure
Merrimack Pharmaceuticals Inc''s (NASDAQ: MACK ) partner announced that Ipsen SA (OTC: IPSEY ) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study did not meet the primary endpoint of overall survival in patients treated with Onivyde … Full story available on Benzinga.com